Irbesartan and Oseltamivir treatment of COVID-19 infection.

Irbesartan and Oseltamivir treatment of COVID-19 infection. - Covid-19 protection trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-001610-38-DK

Enrollment

Registered

2020-04-07

Start date

2020-09-16

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The combined treatment in this trial will be used to treat patients with Covid-19 infection in order to prevent the patients need for further treatment in a hospital. MedDRA version: 23.0 Level: LLT Classification code 10084382 Term: Coronavirus disease 2019 System Organ Class: 100000004862

Interventions

Trade Name: Aprovel Pharmaceutical Form: Tablet Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients age 50-89 years and Covid-19 positiv and home. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 40

Exclusion criteria

Exclusion criteria: Actual treatment with ACE-inhibitor, AT-II receptor antagonist or diuretics Blood pressure below 110/60 Pregnancy Allergy to Irbesartan or Oseltamivir

Design outcomes

Primary

Measure	Time frame
Main Objective: To prevent progression of Covid-19 infections in Covid possitive patient not yet admitted to hospital. The objective is, that the active treated patient will not need further treatment during stay in a hospital.;Secondary Objective: If the patients should need hospital treatment, the secondary objective is to prevent progression of the infection causing need for invasive treatment.;Primary end point(s): Preventing patients with Covid-19 infection treated at home in hospitalizing for this diseace.;Timepoint(s) of evaluation of this end point: 14 days	—

Measure

Time frame

Main Objective: To prevent progression of Covid-19 infections in Covid possitive patient not yet admitted to hospital. The objective is, that the active treated patient will not need further treatment during stay in a hospital.;Secondary Objective: If the patients should need hospital treatment, the secondary objective is to prevent progression of the infection causing need for invasive treatment.;Primary end point(s): Preventing patients with Covid-19 infection treated at home in hospitalizing for this diseace.;Timepoint(s) of evaluation of this end point: 14 days

—

Secondary

Measure	Time frame
Secondary end point(s): Reduction of Covid-19 induced symptoms and diseace duration;Timepoint(s) of evaluation of this end point: 14 days	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026